Company Profile

Hemocleanse Inc
Profile last edited on: 1/20/15      CAGE: 47KV5      UEI:

Business Identifier: Sorbent chemicals and hemodialysis o
Year Founded
1989
First Award
1994
Latest Award
2005
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3601 Sagamore Parkway North Suite B
Lafayette, IN 47904
   (765) 742-9392
   inquiries@hemocleanse.com
   www.hemocleanse.com
Location: Single
Congr. District: 04
County: Tippecanoe

Public Profile

HemoCleanse, Inc. spun out of Ash Medical Systems which had been active in SBIR from the earliest days. grounded inteh work of two men of very different background and aras of expertise - Robert B. Truitt MSE, MBA and Stephen R. Ash MD, FACP HemoCleanse focused on application of sorbents to dialysis therapy. Sorbent regeneration of dialysate allowed creation of dialysis therapies that could remove various toxins specifically, minimize the need for water, and allow machines to be easily implemented in the home and other locations outside of the classic in-center dialysis unit. A number of successful products resulted: BioLogic-HD™ Sorbent Dialysis Machine (FDA approved for treatment of kidney failure in 1986) BioLogic-DT™ “Liver Dialysis” Machine (FDA approved for treatment of hepatic coma in 1996) Allient™ Dialysis Machine (FDA approved for treatment of kidney failure in 2006) Other products ahve followed, many brought to use condition by an active program of new company formation and corporate s

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2005 2 NIH $1,011,543
Project Title: Pheresis Treatment of Bioterrorism-Induced Sepsis
1999 1 NIH $100,000
Project Title: Sub-Q Ultrafilter/Infusion Device (Squid) For Insulin
1998 1 NIH $100,000
Project Title: DNA Charcoal Plasma Sorption for Treatment of SLE
1998 1 NIH $99,946
Project Title: Bioreactor With Direct Plasma Contact For Liver Assist
1995 1 NIH $100,000
Project Title: Liver Assist by Push-Pull Sorbent-Regenerative Pheresis

Key People / Management

  Robert B Truitt -- President

  Stephen R Ash -- Chairman of the Board of Directors and the Director, Research and Development

  Nels Bergmark

Company News

There are no news available.